103 Risk prediction of implant loss following implant-based breast reconstruction Permanent implant 1375 (35.1) 112 (38.0) 358 (36.1) 18 (30.5) Tissue expander 2538 (64.9) 183 (62.0) 635 (63.9) 41 (69.5) Nipple preserving 1030 (31.0) 80 (33.1) 0.510 262 (31.4) 21 (45.7) 0.044 Missing 593 53 159 13 Prepectoral placement 309 (9.2) 42 (16.2) <0.001 75 (8.9) 8 (16.0) 0.125 Missing 539 35 147 9 Concurrent mastopexy 112 (3.3) 9 (3.5) 0.894 24 (2.8) 4 (7.8) 0.069 Missing 112 9 24 4 Drains 3727 (95.2) 282 (95.6) 0.760 951 (95.8) 56 (94.9) 0.712 Missing 7 0 6 0 Volume permanent implant* 375 (290-475) 418 (353-495) 0.002 385 (295-495) 430 (350-510) 0.147 Maximum volume TE** 450 (350-550) 450 (400-575) 0.033 450 (355-550) 525 (350-550) 0.291 Intraoperative volume TE** 0.011 0.022 <100 659 (27.8) 45 (24.7) 175 (29.2) 15 (35.7) 100-200 1448 (61.0) 103 (56.6) 366 (61.0) 18 (42.9) >200 267 (11.2) 34 (18.7) 59 (9.8) 9 (21.4) Missing 148 17 32 2 Adjuvant radiotherapy 196 (7.2) 18 (8.6) 0.457 57 (8.4) 2 (4.7) 0.381 Missing 1199 86 317 16 Postoperative antibiotics 2090 (60.5) 158 (60.3) 0.961 535 (61.6) 30 (56.6) 0.472 Missing 456 33 124 6 Baseline comparisons of the training cohort and validation cohort, stratified for implant loss. Data are n (%), mean ± SD or median (IQR). Statistically significant P-values are denoted in italic. ASA indicates American Association of Anesthesiologists; BMI, body mass index; TE, tissue expander. *Data of permanent implants within training cohort (n=1606) and validation cohort (n=418). **Data of TEs within training cohort (n=2969) and validation cohort (n=706). 7
RkJQdWJsaXNoZXIy MTk4NDMw